Fusion Biopsy Market Size

Fusion Biopsy Market Size

The global fusion biopsy market size was valued at USD 829.1 million in 2024 and is expected to exhibit growth at a CAGR of 9.9% from 2025 to 2034. High market growth can be attributed to the increasing prevalence of prostate cancer, growing awareness and screening programs, and supportive government policies and reimbursement, among other contributing factors.

To get key market trends

  Download Free Sample

Fusion biopsy is an advanced diagnostic technique that combines MRI and ultrasound imaging to accurately identify and target suspicious tissue areas for biopsy, particularly in organs like the prostate. Prostate cancer ranks among the most prevalent cancers in men, particularly affecting older adults. According to the National Cancer Institute, approximately 248,530 new cases of prostate cancer were diagnosed in the U.S. in 2023. The rising incidence can be attributed to an aging population as well as heightened awareness and screening efforts. Conventional biopsy methods often fall short in precision, leading to missed diagnoses or underestimation of the disease's stage.

In contrast, fusion biopsy enhances accuracy by integrating magnetic resonance imaging (MRI) with real-time ultrasound imaging, effectively pinpointing suspicious areas within the prostate. Additionally, as more patients opt for active surveillance for low-risk prostate cancer, there is a growing need for highly accurate diagnostic tools like fusion biopsy. Fusion biopsy enables regular, precise monitoring of prostate changes, helping healthcare providers manage patients on active surveillance more effectively. This capability has made fusion biopsy an essential tool in many urology practices, further driving its demand within the market.